METASTATIC COLORECTAL CANCER

This study tests whether adding two drugs (cetuximab and envafolimab) to a strong chemotherapy mix works better than the standard treatment for people with a specific type of advanced left-side colorectal cancer. About 198 adults with RAS/BRAF wild-type, MSS tumors that cannot be…

This study tests whether adding two targeted drugs (sotorasib and panitumumab) to standard chemotherapy helps people with a specific type of advanced colorectal cancer (KRAS G12C mutation) live longer without their cancer growing. About 450 people who have not had prior treatment…

This study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy for people with metastatic colorectal cancer (cancer that has spread). About 390 adults will take part. The goal is to see if the new combination shrinks tumors and is safe. …

This study tests a new drug called JS212, given with other cancer medicines, in 80 adults with metastatic colorectal cancer that has not been treated before. The goal is to see if the combination is safe and can shrink tumors. JS212 targets two proteins on cancer cells to try to …

This early-phase study tests a new drug called BBO-10203 in about 392 adults with advanced solid tumors (like breast, lung, or colorectal cancer) that have not responded to other treatments. The drug works by blocking a key cancer growth pathway. The main goals are to find the sa…

This study looks at how well a biosimilar version of bevacizumab (Elovie) works and how safe it is for people with advanced colorectal cancer that cannot be removed by surgery. About 133 adults will receive the drug as their first treatment. Researchers will track how long the tr…

This study is for people with advanced colorectal cancer that didn't respond to or caused side effects from first-line treatment. It tests a combination of chemotherapy drugs (Levoleucovorin, 5-FU, and liposomal irinotecan) with or without targeted therapies (cetuximab or bevaciz…

This study tests an experimental drug called ART0380, taken as a pill, for people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with standard chemotherapies (gemcitabine or irinotecan). About 442 …

This study tests whether combining two drugs, fruquintinib and tislelizumab, can help people with a specific type of advanced colorectal cancer that has not spread to the liver. About 140 adults with microsatellite stable (MSS) tumors will take part. The goal is to see if the com…

This study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment group based on specific biomarkers found in their tumor. The goal is to see if the…

This study tests a drug called enfortumab vedotin in people with advanced colorectal or liver cancer that has not responded to other treatments. The goal is to see if the drug can shrink tumors. About 40 adults will take part, and they will receive the drug through an IV.

This study tests an experimental treatment for people with metastatic cancers (colorectal, pancreatic, ovarian, breast, and neuroendocrine tumors) that have not responded to standard therapy. Doctors take white blood cells from a patient's tumor, grow the most cancer-fighting one…

This study tests a combination of five drugs (FLIRT plus bevacizumab) as a first treatment for people with a specific genetic type of advanced colorectal cancer that has spread. The cancer must have a silenced MGMT gene and be microsatellite stable. The goal is to find the safest…

This study tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has not responded to prior therapies. About 1,020 adults who have already tried several standard treatments will participate. …

This early-phase study is testing a new treatment for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step approach: first, an antibody homes in on cancer cells, then a radioactive particle delivers targeted rad…

This early-stage trial is testing a new drug called ulixertinib, given together with cetuximab and/or encorafenib, for people with advanced colorectal cancer that has spread and hasn't responded to prior treatments. The main goal is to find the safest dose and check for side effe…

This study tests whether adding a new drug (BNT314) to an existing immunotherapy (BNT327) and chemotherapy can help people with advanced colorectal cancer that didn't respond to first-line treatment. About 482 adults with a specific type of colorectal cancer (MSS/pMMR) will recei…

This study tests a new drug called EMB-01 in people with advanced colorectal cancer that has come back or spread. About 54 adults will be randomly assigned to receive the drug either once a week or on a different schedule. The goal is to see if the drug can shrink tumors and to c…

This study tests a drug called ivonescimab in 90 adults with metastatic colorectal cancer that has already been treated. The drug targets both the immune system and blood vessel growth to help control the cancer. Researchers will monitor safety and side effects.

This study tests an experimental drug called RBS2418 in people with advanced colorectal cancer that has spread and is no longer responding to standard treatments. The drug works by helping the body's immune system recognize and attack cancer cells. About 150 adults will receive e…

This study is for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. It tests whether a combination of three drugs (adagrasib, cetuximab, and cemiplimab) can help control the cancer. The goal is to manage the disease, not cure it, and rese…

This early-stage trial tests a new treatment for people with metastatic colorectal or prostate cancer. The treatment uses immune cells (TILs) taken from the patient's own tumor, grown in a lab, and then given back to the patient multiple times. The main goals are to see if it is …

This study tests new drug combinations in people with metastatic colorectal cancer that has spread. The goal is to see if these treatments can shrink tumors or slow cancer growth. About 120 adults with measurable disease and good performance status will participate. The trial foc…

This study is for people with advanced colorectal cancer that has a certain genetic makeup (RAS/BRAF wild type) in the tumor but shows a different genetic change (RAS mutation) in a blood test. The goal is to see if a combination of chemotherapy (FOLFIRI) plus a drug called bevac…

This study tests whether a three-drug combination (liposomal irinotecan, TAS102, and bevacizumab) can help people with advanced colorectal cancer that has stopped responding to standard treatments. About 50 adults with mismatch repair proficient tumors who have already tried mult…

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors.…

This study compares a new drug, RPH-030, to an existing one, Vectibix, for people with a certain type of advanced colorectal cancer. About 180 participants will receive either drug along with standard chemotherapy. The goal is to see if the new drug works similarly and is as safe…

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study is testing whether a special PET scan can identify an aggressive form of colorectal cancer called CMS4 without taking tissue samples. About 45 people with colorectal cancer that has spread to the liver will get the scan before surgery. If it works, doctors could use th…

This study aims to create a mindfulness program designed for couples dealing with metastatic colorectal cancer. Researchers will interview patients, their partners, and clinicians to understand their needs and preferences. The goal is to develop a program that helps reduce emotio…

This study follows 1,000 people with metastatic colorectal cancer whose first chemotherapy stopped working. Researchers will record which second or later treatments doctors choose and how long patients live or stay cancer-free. No new drug is tested; the goal is to learn from rea…

This study gathers medical information and biological samples from 400 adults with metastatic colorectal cancer that has a specific genetic change called BRAFV600E. The goal is to learn how this cancer is treated in real-world settings and how long people live. No new treatments …